STOCK TITAN
  1. Home
  2. Sec-filings
  3. CANF
  4. [Form 3] Can-Fite BioPharma Ltd. Initial Statement of Beneficial Ownership

Can-Fite BioPharma (CANF) VP details option grants in new Form 3

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. VP Business Development Sari Fishman filed an initial Form 3 showing holdings of multiple option grants to purchase Ordinary Shares. These options were granted between 2017 and 2025 with exercise prices originally set in New Israeli Shekels and translated into U.S. dollars.

Some option grants are already fully vested and exercisable, while others vest in scheduled quarterly installments between 2026 and 2029, contingent on continued service. To qualify for Israeli Section 102 tax benefits, the options are held in the name of a trustee.

Positive

  • None.

Negative

  • None.
Insider Fishman Sari
Role VP Business Development
Type Security Shares Price Value
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
holding Options to Purchase Ordinary Shares -- -- --
Holdings After Transaction: Options to Purchase Ordinary Shares — 6,447 shares (Direct)
Footnotes (11)
  1. F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
  2. F2. These options are fully vested and exercisable as of the date hereof.
  3. F3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 10,986, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
  4. F4. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,539, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
  5. F5. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,032, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
  6. F6. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
  7. F7. The exercise price of this option, originally denominated in NIS in the amount of NIS 768.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
  8. F8. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 437 options are vested, and the remaining 63 options vest in two equal quarterly installments beginning 04/17/2026 and ending 07/17/2026 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
  9. F9. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,145 options are vested, and the remaining 521 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
  10. F10. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 728 options are vested, and the remaining 938 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
  11. F11. The exercise price of this option, originally denominated in NIS in the amount of NIS 54, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 312 options are vested, and the remaining 1,354 options vest in thirteen equal quarterly installments beginning 04/29/2026 and ending 04/29/2029 subject to the Reporting Person's continued service to the Issuer as of such vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does the Can-Fite (CANF) Form 3 filing by Sari Fishman show?
The Form 3 shows that VP Business Development Sari Fishman holds several option grants to purchase Ordinary Shares. These options span grants from 2017 to 2025, with varying exercise prices and vesting schedules extending through 2029 under Can-Fite’s share option plans.

What type of securities does Sari Fishman hold in Can-Fite (CANF)?
Sari Fishman holds Options to Purchase Ordinary Shares of Can-Fite BioPharma Ltd. Each option grant has a specified exercise price and expiration date, and is linked to the company’s 2003, 2013, or 2023 share option plans as described in the filing footnotes.

How do Sari Fishman’s Can-Fite (CANF) options vest over time?
Some of Fishman’s options are already fully vested and exercisable, while others vest in equal quarterly installments. The footnotes state vesting dates beginning in April 2026 and continuing through April 2029, subject to continued service with Can-Fite on each vesting date.

Why are Can-Fite (CANF) options held through a trustee under Section 102?
To qualify for certain Israeli tax benefits under Section 102 of the Israeli Tax Ordinance, employee securities under Can-Fite’s share option plans must be registered in the name of a trustee. The filing explains this structure for the options reported for Sari Fishman.

How are the Can-Fite (CANF) option exercise prices presented in the Form 3?
The filing notes that each exercise price was originally denominated in New Israeli Shekels and is shown in U.S. dollars. Conversion uses the Bank of Israel exchange rate of NIS 3.106 to USD 1.00 as of March 11, 2026 for presentation purposes.

Do any of Sari Fishman’s Can-Fite (CANF) options remain unvested?
Yes. Several grants include both vested and unvested portions. The footnotes specify that hundreds of options per grant vest over future quarterly installments between 2026 and 2029, conditioned on Fishman’s continued service with Can-Fite on each scheduled vesting date.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Fishman Sari
(Last)(First)(Middle)
C/O CAN-FITE BIOPHARMA LTD.
26 BEN GURION STREET
(Street)
RAMAT GAN5257346
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Can-Fite BioPharma Ltd. [ CANF ]
3a. Foreign Trading Symbol
[CANF.TA] 		5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
VP Business Development
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Options to Purchase Ordinary Shares(1)(2)07/24/201704/23/2027Ordinary Shares26(2)$3,537.03(3)D
Options to Purchase Ordinary Shares(1)(2)03/28/201712/28/2027Ordinary Shares50(2)$2,427.24(4)D
Options to Purchase Ordinary Shares(1)(2)01/07/201901/07/2029Ordinary Shares40(2)$2,264.01(5)D
Options to Purchase Ordinary Shares(1)(2)08/27/202005/27/2030Ordinary Shares333(2)$241.47(6)D
Options to Purchase Ordinary Shares(1)(2)04/13/202104/13/2031Ordinary Shares500(2)$247.36(7)D
Options to Purchase Ordinary Shares(1)(8)07/17/202207/16/2032Ordinary Shares500(8)$241.47(8)D
Options to Purchase Ordinary Shares(1)(9)08/01/202304/30/2033Ordinary Shares1,666(9)$25.21(9)D
Options to Purchase Ordinary Shares(1)(10)05/07/202405/07/2034Ordinary Shares1,666(10)$26.56(10)D
Options to Purchase Ordinary Shares(1)(11)07/29/202504/29/2035Ordinary Shares1,666(11)$17.39(11)D
Explanation of Responses:
1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2003 Share Option Plan, 2013 Share Option Plan and 2023 Share Option Plan must be registered in the name of a trustee.
2. These options are fully vested and exercisable as of the date hereof.
3. The exercise price of this option, originally denominated in New Israeli Shekels ("NIS") in the amount of NIS 10,986, is presented in the table in U.S. dollars ("USD") based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
4. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,539, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
5. The exercise price of this option, originally denominated in NIS in the amount of NIS 7,032, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
6. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
7. The exercise price of this option, originally denominated in NIS in the amount of NIS 768.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00.
8. The exercise price of this option, originally denominated in NIS in the amount of NIS 750, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 437 options are vested, and the remaining 63 options vest in two equal quarterly installments beginning 04/17/2026 and ending 07/17/2026 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
9. The exercise price of this option, originally denominated in NIS in the amount of NIS 78.3, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 1,145 options are vested, and the remaining 521 options vest in five equal quarterly installments beginning 04/01/2026 and ending 04/01/2027 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
10. The exercise price of this option, originally denominated in NIS in the amount of NIS 82.5, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 728 options are vested, and the remaining 938 options vest in nine equal quarterly installments beginning 05/07/2026 and ending 05/07/2028 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
11. The exercise price of this option, originally denominated in NIS in the amount of NIS 54, is presented in the table in USD based on the exchange rate reported by the Bank of Israel on March 11, 2026, which was NIS 3.106 = USD 1.00. Of the options reported herein 312 options are vested, and the remaining 1,354 options vest in thirteen equal quarterly installments beginning 04/29/2026 and ending 04/29/2029 subject to the Reporting Person's continued service to the Issuer as of such vesting date.
/s/ Sari Fishman03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR